Use of angiotensin-converting enzyme (ACE) inhibitors and statins do not reduce the risk of impaired mobility in older adults, a new study finds.
Impairments in mobility are common in older adults, with 15% of older men and 23% of older women unable to walk two to three blocks.
Chronic inflammation has been identified as a factor leading to a decline in functional status, including mobility. Both ACE inhibitors and statins may decrease systemic inflammation
In addition, ACE inhibitors may have a direct effect on muscle mass.
To see if these medications would indirectly have a positive impact on mobility, the researchers followed 3,055 healthy older adults, who had no mobility problems at baseline, for 6.5 years.
At baseline, the participants were in their 70s and had no difficulty walking a quarter-mile, climbing 10 steps, or performing basic activities of daily living; 15.2% used ACE inhibitors and 12.9% used statins. By year 6, ACE inhibitor use increased to 25.6% and statin use to 28.6%.
At the end of the 6.5-year study, 49.8% of the remaining adults had developed mobility limitation.
In separate multivariable models, neither ACE inhibitor use nor statin use was significantly associated with lower risk of mobility limitation.
For more info, see Gray et al. (2011). iAngiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: The Health, Aging and Body Composition Study. Journal of the American Geriatrics Society, 59(12), 2226-2232.